DEFA14A: ENDRA Life Sciences Faces Nasdaq Delisting After Share Price Drops Below $0.10

ENDRA Life Sciences is appealing a Nasdaq delisting determination after its stock price fell below $0.10, and is seeking a reverse stock split at its upcoming annual meeting to regain compliance.

Summary

• ENDRA Life Sciences Inc. received a notice from Nasdaq on July 15, 2024, indicating that its common stock price had closed below $0.10 per share for 10 consecutive trading days.
• As a result, Nasdaq determined to delist the company's common stock from The Nasdaq Capital Market.
• ENDRA requested a hearing before a Nasdaq Hearings Panel on July 16, 2024, to appeal the delisting determination, which automatically stays the delisting action pending the hearing.
• The company is seeking stockholder approval for a reverse stock split at its annual meeting on August 6, 2024, with a ratio between 1-for-20 and 1-for-50, to regain compliance with the Nasdaq minimum bid price requirement.
• There is no assurance that the Panel will grant the Company any compliance period or that the Company will ultimately regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance with Nasdaq listing requirements. The proposed reverse stock split is a reactive measure, and its success is not guaranteed.

Positives

• ENDRA has requested a hearing to appeal the delisting determination, which temporarily stays the delisting process.
• The company is actively seeking a solution to regain compliance with Nasdaq listing requirements through a proposed reverse stock split.

Negatives

• ENDRA's stock price has fallen below $0.10, triggering a delisting notice from Nasdaq.
• There is no guarantee that the Nasdaq Hearings Panel will grant a compliance period or that ENDRA will regain compliance with listing requirements.

Risks

• The Nasdaq Hearings Panel may not grant ENDRA a compliance period.
• The reverse stock split may not be approved by stockholders or may not be sufficient to raise the stock price above the minimum bid price requirement.
• Failure to regain compliance with Nasdaq listing requirements will result in delisting from The Nasdaq Capital Market.

Future Outlook

The company plans to appeal the delisting determination and seek stockholder approval for a reverse stock split to regain compliance with Nasdaq listing requirements. The outcome of the hearing and the success of the reverse stock split are uncertain.

Industry Context

Delisting notices are not uncommon for small-cap companies, particularly in the biotechnology sector, which can be subject to volatile stock prices based on clinical trial results, regulatory approvals, and funding availability. Companies in similar situations often pursue reverse stock splits or other measures to boost their share price and maintain their listing.

Comparison to Industry Standards

• Many small-cap biotech companies facing similar delisting threats have opted for reverse stock splits to artificially inflate their stock price and meet minimum listing requirements.
• For example, companies like 'TherapeuticsMD' (now Innovus Pharma) and 'Aeterna Zentaris' have previously implemented reverse stock splits to avoid delisting from Nasdaq.
• The success of these strategies varies, and often depends on the underlying financial health and future prospects of the company.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting, which could reduce liquidity and investment value.
• Employees may experience uncertainty regarding the company's future and job security.
• The company's ability to raise capital and fund its operations could be negatively impacted.

Next Steps

• ENDRA will attend a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
• The company will hold its annual meeting on August 6, 2024, to seek stockholder approval for a reverse stock split.
• ENDRA will monitor its stock price and consider other options to regain compliance with the Minimum Bid Price Requirement.

Key Dates

Keywords

delisting, Nasdaq, reverse stock split, minimum bid price, compliance, ENDRA Life Sciences, stock price